Efflux Pumps Are Involved in the Defense of Gram-Negative Bacteria against the Natural Products Isobavachalcone and Diospyrone | Zendy

Victor Kuete | Zendy; B. Ngameni | Zendy; Jean Gustave Tangmouo | Zendy; JeanMichel Bolla | Zendy; Sandrine Alibert | Zendy; Bonaventure T. Ngadjui | Zendy; JeanMarie Pagès | Zendy

Open Access

Efflux Pumps Are Involved in the Defense of Gram-Negative Bacteria against the Natural Products Isobavachalcone and Diospyrone

Author(s) -

Victor Kuete,

B. Ngameni,

Jean Gustave Tangmouo,

JeanMichel Bolla,

Sandrine Alibert,

Bonaventure T. Ngadjui,

JeanMarie Pagès

Publication year - 2010

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01533-09

Subject(s) - efflux , bacteria , gram negative bacteria , gram , microbiology and biotechnology , biology , multiple drug resistance , antibiotics , gram positive bacteria , antibacterial activity , chemistry , biochemistry , escherichia coli , gene , genetics

The activities of two naturally occurring compounds, isobavachalcone and diospyrone, against documented strains and multidrug-resistant (MDR) Gram-negative bacterial isolates were evaluated. The results indicated that the two compounds exhibited intrinsic antibacterial activity against several Gram-negative bacteria, and their activities were significantly improved in the presence of an efflux pump inhibitor (MIC values decreased to below 10 microg/ml). In addition, the activities of isobavachalcone and diospyrone against various strains exhibiting deletions of the major efflux pump components (AcrAB, TolC) were significantly increased. The overall results indicate that isobavachalcone and diospyrone could be candidates for the development of new drugs against MDR strains and that their use in combination with efflux pump inhibitors reinforces their activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research